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EVALUATION OF THE RATIONALE FOR LINGUAL TONSILLECTOMY 
IN THE DIAGNOSTIC WORK-UP OF HEAD AND NECK SQUAMOUS 
CELL CARCINOMA OF UNKNOWN PRIMARY: IMPACT OF 
IDENTIFYING SMALL TONGUE BASE PRIMARY TUMOURS ON IMRT 
CHARACTERISTICS AND CLINICAL OUTCOMES  
Ali Hosni, Peter Dixon, Anupam Rishi, Michael Au, Wei Xu, David 
Goldstein, Shao Hui Huang, Brian O’Sullivan, John Waldron, 
John R. de Almeida, Scott V. Bratman 
University of Toronto, Toronto, ON 
 
Purpose: Transoral robotic surgery (TORS) and laser 
microsurgery (TLM) have been utilized to perform lingual 
tonsillectomy in the diagnostic work-up of head and neck 
squamous cell carcinoma of unknown primary (CUP). We 
evaluated the potential therapeutic value for this approach by 
comparing differences in radiotherapy characteristics and 
clinical outcomes for CUP and small base-of-tongue (BOT) 
tumours. 
Methods and Materials: Retrospective review of BOT (T1N1-3M0) 
and CUP (T0N1-3M0) patients treated with intensity-modulated 
radiotherapy (IMRT) at our institution between 2005-2013 with 
known p16 immunohistochemistry status. The IMRT 
characteristics, mucosal (CTV-T) and nodal (CTV-N) clinical 
target volumes, and organ at risk (OAR) dosimetry, were 
obtained. Local (LC), regional (RC), distant control (DC), cause-
specific (CSS), overall survival (OS) and RTOG Grade ≥ 3 late 
toxicity (LT) were analyzed.  
Results: Fifty-four BOT (93% p16-positive) and 61 CUP (62% p16-
positive) patients were identified. Respective N classifications 
included: N1 (15 versus 8%), N2a (17 versus 31%), N2b (28 versus 
36%), N2c (24 versus 8%) and N3 (17 versus 16%). High-dose CTV-
T was prescribed in 100% of BOT and 38% of CUP patients (p < 
0.001). Low-dose CTV-T included mucosal sites outside of the 
oropharynx (i.e., nasopharynx, hypopharynx, and/or larynx) in 
0% of BOT and 26% of CUP patients (p < 0.001), with greater 
volume of low-dose CTV-T in CUP than BOT patients (113 ± 8 
versus 84 ± 6 cm3, p = 0.003). Bilateral neck irradiation was used 
in 53/54 (98%) BOT and 46/61 (75%) CUP patients (p < 0.001). 
OAR dosimetry demonstrated that BOT patients received higher 
maximum dose (Dmax) to the mandible (71 +/- 4.5 versus 67.2 
+/-  6.7 Gy, p = 0.001), with a trend toward higher laryngeal 
Dmax (66.1 +/- 7.6 versus 62.8+/-9.3 Gy, p = 0.059) and lower 
average dose (Dmean) to the larynx (43.8 +/- 7.5 versus 47.1 +/- 
10.7 Gy, p = 0.071). There were no significant differences in 
Dmax to inferior constrictor muscle or esophagus, and Dmean to 
mandible, inferior constrictor muscle or esophagus (p > 0.05 for 
all). The three-year LC, RC, DC, CSS and OS for p16-positive BOT 
versus CUP patients were 100% versus 95%, 98% versus 100%, 94% 
versus 91%, 94% versus 93%, 88% versus 91%, respectively, while 
in p16-negative BOT versus CUP patients were 75% versus 100%, 
75% versus 82%, 100% versus 85%, 75% versus 85%, 50% versus 74%, 
respectively (p > 0.05 for all). Grade 3 LT recorded in two (3%) 
CUP patients (neck fibrosis) and five (9%) BOT patients (two neck 
fibrosis, two osteoradionecrosis, and one dysphagia). 
Conclusions: Patients treated with IMRT for CUP or small BOT 
tumours had similar clinical outcomes. Performing TORS or TLM 
to identify small BOT tumours would lead to a reduction in the 
volume of low-dose CTV-T, with more frequent use of high-dose 
CTV-T and bilateral neck irradiation. Future studies are required 
to investigate the potential impact of these volumetric and 
dosimetric differences on quality-of-life and functional 
outcomes. 
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INFORMATION NEEDS OF PATIENTS DIAGNOSED WITH HEAD AND 
NECK CANCER UNDERGOING RADIATION THERAPY: A SURVEY OF 
PATIENT SATISFACTION  
Cecilia Kim, Ruth Dillon, Luminita Nica, Mira Keyes, Eric 
Berthelet 
British Columbia Cancer Agency, Vancouver Centre, Vancouver, 
BC 
Purpose: A comprehensive revised patient education booklet, 
for patients diagnosed with head and neck cancer, was 
developed at our centre. This revised education booklet 
consolidates information from various sources in a single 
document. 
The objectives of this study are: 1) to identify patients’ reported 
informational needs and areas for improvement in patient 
education; and 2) to evaluate the level of patient satisfaction 
with the written information they received. 
Methods and Materials: A sample of 100 patients will be 
surveyed. The first cohort of patients will receive the original 
education material. The second cohort of patients will receive 
the education material revised. The survey will be administered 
to both cohorts of patients at two points during their treatment 
pathway: at the participants’ last radiation treatment 
appointment and at the six week follow up appointment.  
A satisfaction survey has been derived from the standard patient 
satisfaction survey currently in use at our institution. Survey’s 
questions evaluate several measures including content, amount, 
ease of understanding and timing of information delivery. 
Results: Data collection is currently ongoing. Qualitative 
responses will be reviewed and categorized using thematic 
analysis. Data from the two patient cohorts will be compared. 
Descriptive statistics will be used for quantitative analysis. 
Independent t-test will be used to test for differences between 
the two cohorts of patients. A rank-sum test will be used to 
determine whether the two groups of respondents differ in their 
average response. Within each cohort, a dependent t-test will be 
used to test for differences between the two time points at 
which the data is collected. 
Conclusions: The information gathered will be used to assess the 
usefulness of the new educational booklet compared to previous 
material. This may help develop site specific educational 
materials to improve our current practice and patient 
satisfaction. 
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DECISIONS, DECISIONS - PATIENT CENTRED DECISION AID FOR 
OROPHARYNGEAL CANCER TREATMENT  
Grace Scott, Jacqueline Lam, David Palma, Kevin Fung, 
Alexander Louie 
University of Western Ontario, London, ON 
 
Purpose: Definitive radiotherapy (RT) with or without 
chemotherapy has been the standard of care for early 
oropharyngeal cancer, achieving excellent oncologic outcomes 
but often with significant toxicities. Trans-Oral Robotic Surgery 
(TORS), a minimally invasive surgical approach, has emerged as 
a promising alternative with initial reports suggesting 
comparable oncological outcomes and excellent functional 
outcomes. Current studies are being performed to compare these 
two modalities in a head-to-head fashion; however, patient 
preferences regarding the choice of RT versus TORS are 
unknown. A Decision Aid was developed to navigate newly-
diagnosed patients through the complex process of deciding 
between the two treatment modalities to best suit their 
individual circumstances. 
Methods and Materials: A Decision Aid was developed on an 
interactive multimedia web platform to enable ease of access in 
multiple settings. It provides a visual description of the 
treatment modalities, including their respective timelines, and 
photographs of treatment-related equipment. Detailing of the 
potential benefits and side effects of each treatment was 
included, with their relative frequencies. Healthy adult 
volunteers (age 18-80) were recruited to pilot test the online 
module and confirm psychometric properties. Following a verbal 
description of a hypothetical diagnosis of early oropharyngeal 
cancer, subjects were guided through the Decision Aid with a 
trained researcher. Subjects were then asked to make a 
preferred treatment based on the assumption of equal 
oncological outcomes. Once established, the survival rate of the 
alternate therapy was increased to establish a treatment 
tradeoff point, in which the preferred strategy would switch. 
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Information regarding the most pertinent side effects were 
collected, as well as the perceived utility of the aid.  
Results: Thirty-two participants (16 men, 16 women) with a 
median age of 34.5 (range 18-64) enrolled in this study. Twenty-
six subjects (81%) selected TORS as their preferred treatment 
option. Tradeoff revealed that participants were willing to 
accept a median score of 10% (range 5-50) decrease in survival 
to maintain their treatment choice. Regarding side effect 
profiles, the most concerning risks of TORS were: bleeding, 
death, stroke and aspiration pneumonia. Whereas, the most 
concerning toxicities of RT were: tooth decay, need of a feeding 
tube, and the risk of secondary malignancy. Finally, all subjects 
indicated that if they would value having a similar tool available 
perchance they are in a similar situation. 
Conclusions: A novel web-based Decision Aid has been developed 
for patients with early oropharyngeal cancer. The finding that 
TORS was preferred over RT in a sample of healthy volunteers 
necessitates confirmation in a cohort of patients with early 
oropharyngeal cancer. This tool holds promise in the era of 
shared-decision making and personalized patient-centred care. 
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DOES MID-TREATMENT CBCT-GUIDED PATIENT REPOSITIONING 
DURING LUNG VMAT IMPACT TARGET COVERAGE? 
Dominique Mathieu, Marie-Pierre Campeau, Robert Doucet, 
Karim Zerouali, Stéphane Bedwani, Houda Bahig, Louise 
Lambert, Thi Trinh Thuc Vu, David Roberge, Édith Filion 
Centre Hospitalier de l'Université de Montréal, Montréal, QC  
 
Purpose: The objectives of this study are to (1) quantify 
intrafraction motion (IFM) during lung volumetric-modulated arc 
therapy (VMAT) and (2) evaluate the impact of mid-treatment 
patient repositioning after cone beam computed tomography 
(CBCT) acquisition upon target coverage. 
Methods and Materials: This analysis included lung tumours 
treated with VMAT between April 2012 and June 2015 with 50-60 
Gy in 3-5 fractions. Treatment planning consisted of a four-
dimensional (4D) CT scan from which an internal target volume 
(ITV) delineation was performed. A 5 mm margin was added in 
all directions to obtain the final planning target volume (PTV). 
Treatment sessions were performed in supine position with a 
customized dual vacuum immobilization device (BodyFIX, Elekta, 
Stockholm, Sweden). All patients underwent pre and mid-
treatment CBCTs to ensure proper repositioning. Following each 
CBCT, a two-step rigid registration was performed by an 
experienced radiation oncologist according to the planning CT, 
taking into account organs at risk (OARs). Bone shift was first 
assessed with a registration of the vertebrae adjacent to the 
lesion. Then, tumour shift was isolated with a soft tissue 
registration by aligning targets. IFM, combining bone and tumour 
shifts, was defined as the target displacement from pre to mid-
treatment CBCT acquisition and was quantified in terms of 
anterior-posterior (AP), cranio-caudal (CC) and medio-lateral 
(ML) amplitudes as well as three-dimensional (3D) vector. For 
patients with IFM ≥ 5 mm, a post-hoc dose calculation analysis 
was performed to assess target coverage impacts of mid-
treatment CBCT-guided repositioning. 
Results: Ninety-seven patients, totalizing 367 fractions, were 
included. Mean (±SD) overall treatment time was 53:02 ± 13:08 
min. Mean time from pre to mid-treatment CBCT acquisition was 
22:58 ± 5:33 min. Mean time to perform mid treatment CBCT 
scan acquisition, registrations and couch repositioning was 15:49 
± 4:14 min. Mean IFM amplitudes were 0.9 ± 1.2 mm, 0.6 ± 1.0 
mm and 0.6 ± 0.8 mm in the AP, CC and ML respectively. IFM was 
< 3 mm and < 5 mm in all directions in respectively 315/367 (86%) 
and 358/367 (98%) fractions. Mean 3D IFM vector was 1.5 ± 1.4 
mm (max = 8.1 mm) and was < 5 mm in 354/367 (96%). Among 
the 13 fractions with IFM vector ≥ 5 mm, 11/13 (85%) were 
dominantly induced by a tumour shift. For all these fractions, 
dose calculation analysis of worst-case scenario indicates that 
ITV coverage would have remained ≥ 95% without mid-treatment 
CBCT-guided patient repositioning. 
Conclusions: For 96% of fractions in patients immobilized with a 
customized BodyFIX dual vacuum bag, the IFM vector was within 
the 5 mm PTV margin used. Mid-treatment CBCT-guided couch 
repositioning did not significantly impact ITV coverage and 
prolonged treatment duration. Mid-treatment imaging may 
remain pertinent for selected patients with strict OAR dose 
constraints. 
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LACK OF DOSE–VOLUME PARAMETER TO PREDICT THE 
DEVELOPMENT OF CHEST WALL PAIN AFTER SBRT FOR LUNG 
CANCER  
Sergio Faria1, Issam El Naqa2, L Ming Wang1 
1McGill University Health Centre, Montreal, QC 
2University of Michigan, Michigan, MI 
 
Purpose: Chest wall (CW) pain is as a possible late toxicity after 
SBRT. Several dosimetric factors have been reported to predict 
it, however, with no clear validation. This article reports our 
institutional experience with CW pain and the search for dose 
constraints for the CW as organ at risk in a homogeneous group 
of patients treated with the same dose and fractionation, 
planned with heterogeneity correction, without any initial dose 
constraint to the CW at the initial planning. 
Material and Methods: Patients with localized lung tumours, 
treated with SBRT the way mentioned above, to a dose of 48 Gy 
in 3 fractions, with the PTV touching the CW were reviewed. CW 
(2 cm expansion) was contoured retrospectively. Using Eclipse 
(Varian) software, common metrics of the absolute volume of the 
CW receiving 30 Gy or more (V30Gy), the intersecting volumes 
(in cm3) between the PTV and CW volumes, the mean dose and 
the max dose of the CW volume were extracted. CW pain was 
graduated by Common Terminology Criteria for Adverse Events 
v3.0. Data analysis and data correlation was carried out using the 
widely used Dose Response Explorer System1 (DREES) software, 
which allows for analytical and data-driven outcome modeling. 
Results: Seventy-five lung lesions in 71 patients met the criteria 
for our study. After a median follow up of 16 months, five 
patients reported CW pain (3 Grade = 3 and 2 Grade = 2). Median 
time for CW pain to manifest was seven months. The median 
volume of CW receiving > 30 Gy was 26 cc (range: 0.1 – 126 cc). 
The V30 Gy volumes (cm3) of the five cases with CW pain were 
15, 15, 20, 47 and 100. For all lesions, mean Dose to CW = 54.2 
± 2.3 Gy. Median max CW dose = 57 Gy. After DREES analysis, no 
correlation between the variables studied and CW pain was 
found. 
Conclusions: CW pain is an important late toxicity after SBRT in 
lung tumours. V30 Gy of the CW has been often used to decrease 
the risk of CW pain, but the volume is not clear. None of the 
common variables (including V30 Gy) analyzed in this study was 
statistically significant for CW pain. Good dosimetric constraints 
to decrease risk of CW pain remain to be determined.  
(1) El Naqa I, et al. Dose response explorer: an integrated open-
source tool for exploring and modelling radiotherapy dose-
volume outcome relationships. Physics in Medicine and Biology 
2006. 
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DO WE REALLY NEED CUSTOMIZED IMMOBILIZATION DEVICES FOR 
MODERN SBRT IN LUNG CANCER?  
Sergio Faria, Iqbal Al Amri, Jessica Gluszko, Horacio Patrocinio 
McGill University Health Centre, Montreal, QC 
 
Purpose: To assess the intra-fraction tumour stability of lung 
cancer patients treated by cone beam computed tomography-
guided (CBCT) stereotactic body radiotherapy (SBRT) without 
any frame or immobilization devices. 
Materials and Methods: Localized lung cancer patients were 
treated with SBRT, positioned supine, with arms held above the 
head, a foam support under the knees and without any further 
immobilization. Internal target volume (ITV) was generated from 
4D-CT simulation around which a 5 mm symmetric PTV margin 
was added. All patients (except one) received 48 Gy in 3 
